Pfizer stock jumped 4.7% on Tuesday after the company issued a mixed outlook for 2025. The pharmaceutical giant expects sales of $61 billion to $64 billion and adjusted earnings per share of $2.80 to $3. This falls short of forecasts, but analysts are cautiously optimistic.
The midpoint of Pfizer’s guidance missed projections, but its earnings guidance was slightly above expectations. Analysts at Edward Jones say this is progress towards a more predictable financial structure.
Pfizer expects its Covid-19 vaccine Comirnaty and oral drug Paxlovid to generate similar sales in 2025 compared to last year. Analysts project $5.03 billion from Comirnaty and $4.99 billion from Paxlovid.
While Pfizer’s guidance is mixed, analysts remain encouraged by the company’s improving new drug pipeline, particularly in cancer treatment. This could offset declining sales due to patent expirations. However, further cost savings efforts may be needed before demand for Covid-19 products stabilizes.
Source: https://www.investors.com/news/technology/pfizer-stock-2025-guidance